Alcon announced the launch of the first fully personalized laser-assisted in situ keratomileusis (LASIK) treatment, Wavelight Plus, in the United States and Canada.
Wavelight Plus leverages ray tracing technology, powered by the Sightmap diagnostic device, to consider a patient’s individual eye shape and vision needs, the company said in a press release.
Based on over 100,000 data points, the device precisely creates a 3-dimensional (3D) model or “Digital Eye Twin” of each patient’s eyes, using a combination of ocular wavefront, biometry, and corneal tomography measurements. The 3D eye model guides a highly personalized procedure to improve visual acuity and correct more complex vision problems. The measurements are done without nomogram inputs, the company said.
According to Alcon, real-world clinical evidence from 200 patients who underwent Wavelight Plus LASIK found that the technology delivered exceptional visual acuity results, which is in line with Alcon’s clinical study.
Key results from Dr. Chandra Bala’s study include:
-
100% of myopic eyes achieved uncorrected distance visual acuity (UDVA) of 20/20 at 3 months.
-
89% of myopic eyes achieved postoperative UDVA of 20/16 and 50% achieved 20/12.5 at 3 months.
-
98% of eyes achieved postoperative UDVA within 1 line of their preoperative corrected distance visual acuity (CDVA) by 3 months.
-
94% of eyes achieved the same or better postoperative CDVA than their preoperative CDVA by 3 months.
Prior to launching in the US and Canada, Wavelight Plus was first launched in China and has since been made available in several European and Asia-Pacific markets. The commercial launch for Wavelight Plus in Canada is late 2025, the company said.